Eli Lilly's Obesity Pill Trails Novo Nordisk in Market Adoption
Despite the launch of Eli Lilly’s Foundayo three months ago, Novo Nordisk’s Wegovy remains dominant in the oral weight loss drug market. JPMorgan research cited by The Wall Street Journal indicates that Wegovy continues to outperform its competitor.
Topics: pharmaceutical market prescription trends weight loss drugs